Meta-analysis of the impact of de novo and acquired EGFR T790M mutations on the prognosis of patients with non-small cell lung cancer receiving EGFR-TKIs

References

• EttingerDSAkerleyWBorghaeiHNon-small cell lung cancerJ Natl Compr Canc Netw201210101236127123054877
   PubMed Web of Science ®Google Scholar
• ReguartNRemonJCommon EGFR-mutated subgroups (Del19/L858R) in advanced non-small-cell lung cancer: chasing better outcomes with tyrosine kinase inhibitorsFuture Oncol20151181245125725629371
   PubMedGoogle Scholar
• SunLMaJTZhangSLZouHWHanCBEfficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab vs chemotherapy or tyrosine kinase inhibitors alone in the treatment of non-small cell lung cancer: a systematic review and meta-analysisMed Oncol201532247325603953
   PubMedGoogle Scholar
• SavasPHughesBSolomonBTargeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancerJ Thorac Dis20135Suppl 5S579S59224163750
   PubMedGoogle Scholar
• KobayashiSBoggonTJDayaramTEGFR mutation and resistance of non-small-cell lung cancer to gefitinibN Engl J Med2005352878679215728811
   PubMed Web of Science ®Google Scholar
• JännePAYangJCKimDWAZD9291 in EGFR inhibitor-resistant non-small-cell lung cancerN Engl J Med2015372181689169925923549
   PubMed Web of Science ®Google Scholar
• YangJRamalingamSSJännePACantariniMMitsudomiTLBA2_PR: osimertinib (AZD9291) in pre-treated pts with T790M-positive advanced NSCLC: updated Phase 1 (P1) and pooled Phase 2 (P2) resultsJ Thorac Oncol2016114 SupplS152S153
   Web of Science ®Google Scholar
• WangSCangSLiuDThird-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancerJ Hematol Oncol2016913427071706
   PubMed Web of Science ®Google Scholar
• HataAKatakamiNYoshiokaHRebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: Comparison between T790M mutation-positive and mutation-negative populationsCancer2013119244325433224105277
   PubMed Web of Science ®Google Scholar
• HeCZhengLXuYLiuMLiYXuJHighly sensitive and noninvasive detection of epidermal growth factor receptor T790M mutation in non-small cell lung cancerClin Chim Acta201342511912423886554
   PubMed Web of Science ®Google Scholar
• IsobeKHataYTochigiNUsefulness of nanofluidic digital PCR arrays to quantify T790M mutation in EGFR-mutant lung adenocarcinomaCancer Genomics Proteomics2015121313725560642
   PubMedGoogle Scholar
• JiWChoiCMRhoJKMechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancerBMC Cancer20131360624369725
   PubMed Web of Science ®Google Scholar
• LiWRenSLiJT790M mutation is associated with better efficacy of treatment beyond progression with EGFR-TKI in advanced NSCLC patientsLung Cancer201484329530024685306
   PubMed Web of Science ®Google Scholar
• NakamuraTSueoka-AraganeNIwanagaKA noninvasive system for monitoring resistance to epidermal growth factor receptor tyrosine kinase inhibitors with plasma DNAJ Thorac Oncol20116101639164821921847
   PubMed Web of Science ®Google Scholar
• OxnardGRArcilaMESimaCSAcquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutationClin Cancer Res20111761616162221135146
   PubMed Web of Science ®Google Scholar
• SakaiKHoriikeAIrwinDLDetection of epidermal growth factor receptor T790M mutation in plasma DNA from patients refractory to epidermal growth factor receptor tyrosine kinase inhibitorCancer Sci201310491198120423721103
   PubMed Web of Science ®Google Scholar
• SorensenBSWuLWeiWMonitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinibCancer2014120243896390125103305
   PubMed Web of Science ®Google Scholar
• SoriaJCWuYLNakagawaKGefitinib/chemotherapy vs chemotherapy in EGFR mutation-positive NSCLC after progression on 1st line gefitinib (IMPRESS study): Final overall survival (OS) analysisAnn Oncol201627suppl_6416454
   Google Scholar
• Sueoka-AraganeNKatakamiNSatouchiMMonitoring EGFR T790M with plasma DNA from lung cancer patients in a prospective observational studyCancer Sci2016107216216726577492
   PubMed Web of Science ®Google Scholar
• SunJMAhnMJChoiYLAhnJSParkKClinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitorsLung Cancer201382229429824035188
   PubMed Web of Science ®Google Scholar
• UramotoHYamadaTYanoSKondoNHasegawaSTanakaFPrognostic value of acquired resistance-related molecules in Japanese patients with NSCLC treated with an EGFR-TKIAnticancer Res20123293785379022993320
   PubMed Web of Science ®Google Scholar
• ZhengDYeXZhangMZPlasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistanceSci Rep201662091326867973
   PubMed Web of Science ®Google Scholar
• OxnardGRThressKSAldenRS135O_PR: Plasma genotyping for predicting benefit from osimertinib in patients (pts) with advanced NSCLCJ Thorac Oncol2016114 SupplS154
   Google Scholar
• ZhouQYangJJChenZHSerial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trialJ Hematol Oncol2016918627619632
   PubMed Web of Science ®Google Scholar
• SuKYChenHYLiKCPretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancerJ Clin Oncol201230443344022215752
   PubMed Web of Science ®Google Scholar
• CostaCMolinaMADrozdowskyjAThe impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trialClin Cancer Res20142072001201024493829
   PubMed Web of Science ®Google Scholar
• FujitaYSudaKKimuraHHighly sensitive detection of EGFR T790M mutation using colony hybridization predicts favorable prognosis of patients with lung cancer harboring activating EGFR mutationJ Thorac Oncol20127111640164422899358
   PubMed Web of Science ®Google Scholar
• KarachaliouNCostaCGimenez-CapitaBRCA1, LMO4, and CtIP mRNA expression in erlotinib-treated non-small-cell lung cancer patients with EGFR mutationsJ Thorac Oncol20138329530023407556
   PubMed Web of Science ®Google Scholar
• LeeYLeeGKLeeYSClinical outcome according to the level of preexisting epidermal growth factor receptor T790M mutation in patients with lung cancer harboring sensitive epidermal growth factor receptor mutationsCancer2014120142090209824737599
   PubMed Web of Science ®Google Scholar
• MaheswaranSSequistLVNagrathSDetection of mutations in EGFR in circulating lung-cancer cellsN Engl J Med2008359436637718596266
   PubMed Web of Science ®Google Scholar
• RosellRMolinaMACostaCPretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutationsClin Cancer Res20111751160116821233402
   PubMed Web of Science ®Google Scholar
• ZhaoJFengHHZhaoJYA sensitive and practical method to detect the T790M mutation in the epidermal growth factor receptorOncol Lett20161142573257927073519
   PubMedGoogle Scholar
• JackmanDPaoWRielyGJClinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancerJ Clin Oncol201028235736019949011
   PubMed Web of Science ®Google Scholar
• MunnZMoolaSRiitanoDLisyKThe development of a critical appraisal tool for use in systematic reviews addressing questions ofInt J Health Policy Manage201433123128
   PubMedGoogle Scholar
• DerSimonianRLairdNMeta-analysis in clinical trialsControl Clin Trials198671771883802833
   PubMed Web of Science ®Google Scholar
• MantelNHaenszelWStatistical aspects of the analysis of data from retrospective studies of diseaseJ Natl Cancer Inst19592271974813655060
   PubMed Web of Science ®Google Scholar
• TierneyJFStewartLAGhersiDBurdettSSydesMRPractical methods for incorporating summary time-to-event data into meta-analysisTrials200781617555582
   PubMed Web of Science ®Google Scholar
• BeggCBMazumdarMOperating characteristics of a rank correlation test for publication biasBiometrics1994504108811017786990
   PubMed Web of Science ®Google Scholar
• EggerMDavey SmithGSchneiderMMinderCBias in meta-analysis detected by a simple, graphical testBMJ199731571096296349310563
   PubMed Web of Science ®Google Scholar
• OhJEAnCHYooNJLeeSHDetection of low-level EGFR T790M mutation in lung cancer tissuesAPMIS2011119740341121635547
   PubMed Web of Science ®Google Scholar
• LeeYLeeGKHwangJAYunTKimHTLeeJSClinical likelihood of sporadic primary EGFR T790M mutation in EGFR-mutant lung cancerClin Lung Cancer2015161465025450875
   PubMed Web of Science ®Google Scholar
• DingDYuYLiZNiuXLuSThe predictive role of pretreatment epidermal growth factor receptor T790M mutation on the progression-free survival of tyrosine-kinase inhibitor-treated non-small cell lung cancer patients: a meta-analysisOnco Targets Ther2014738739324623981
   PubMed Web of Science ®Google Scholar
• MulloyRFerrandAKimYEpidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinibCancer Res20076752325233017332364
   PubMed Web of Science ®Google Scholar
• ChmieleckiJFooJOxnardGROptimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modelingSci Transl Med201139090ra59
   PubMed Web of Science ®Google Scholar
• WangZChenRWangSQuantification and dynamic monitoring of EGFR T790M in plasma cell-free DNA by digital PCR for prognosis of EGFR-TKI treatment in advanced NSCLCPLoS One2014911e11078025405807
   PubMed Web of Science ®Google Scholar
• StahelABDafniUGautschiOA phase II trial of erlotinib (E) and bevacizumab (B) in parents with advanced non-small-cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations with and without T790M mutation. The Spanish Lung Cancer Group (SLCG) and the European Thoracic Oncology Platform (ETOP) BELIEF trialEur J Cancer201551Suppl 3S711S712
   Google Scholar
• NguyenKSKobayashiSCostaDBAcquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathwayClin Lung Cancer200910428128919632948
   PubMed Web of Science ®Google Scholar
• KuiperJLHeidemanDAThunnissenEIncidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patientsLung Cancer2014851192424768581
   PubMed Web of Science ®Google Scholar
• WangSSongYYanFLiuDMechanisms of resistance to third-generation EGFR tyrosine kinase inhibitorsFront Med201610438338827770386
   PubMed Web of Science ®Google Scholar
• YuHArcilaMERekhtmanNAnalysis of mechanisms of acquired resistance to EGFR TKI therapy in 155 patients with EGFR-mutant lung cancersClin Cancer Res20131982240224723470965
   PubMed Web of Science ®Google Scholar
• OtsukaKHataATakeshitaJEGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancerCancer Chemother Pharmacol201576483584126349474
   PubMed Web of Science ®Google Scholar
• OxnardGRThressKSAldenRSAssociation between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancerJ Clin Oncol201634283375338227354477
   PubMed Web of Science ®Google Scholar
• YangJCAhnMJKimDWOsimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA Study Phase II Extension ComponentJ Clin Oncol2017 JCO2016703223
   Google Scholar
• YeXZhuZZZhongLHigh T790M detection rate in TKI-naive NSCLC with EGFR sensitive mutation: truth or artifact?J Thorac Oncol2013891118112023945382
   PubMed Web of Science ®Google Scholar
• YuHAArcilaMEHellmannMDKrisMGLadanyiMRielyGJPoor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testingAnn Oncol201425242342824478319
   PubMed Web of Science ®Google Scholar
• NagaiYMiyazawaHHuqunGenetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clampCancer Res200565167276728216105816
   PubMed Web of Science ®Google Scholar